Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Constantine S. Tam(The Alfred Hospital), Kerry A. Rogers(The Ohio State University), Danielle M. Brander(Duke University), Alexey V. Danilov(City of Hope), Jacqueline C. Barrientos(Mount Sinai Medical Center), Chaitra S. Ujjani(Fred Hutch Cancer Center), Philip A. Thompson(The Royal Melbourne Hospital), Ying Huang(Linyi University), Sameer A. Parikh(Mayo Clinic), Robert M. Stern(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 28
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k